X.NOV
Héricourt, Franche-Comte, France
About X.NOV
X.NOV is a healthcare company specializing in the design, manufacture, marketing and sale of orthopaedic medical devices for hip and knee surgery and associated instrumentation. Perpetual research of better solutions for the patients and health professionals require surpassing our limits. Therefore X.NOV decided to organise by business units to acquire international skills. Our organisation also benefits from optimal efficiency which helps our manner of working and to improve our creativity. Associated with diverse creative teams, the three founders X.NOV company all come from the medical industry. They have more than 30 years’ experience in the field of medical devices and particularly in Research and Development (R&D). Innovation is at the heart of the company’s strategy. Don’t be satisfied with what currently exists, we improve and research the ideas which will set us apart in meeting the requirements and safety for our patients, which is one of our main objectives. Our R&D department has a testing lab where the goal is to thoroughly test our implants in order to test the functioning of the products in extreme conditions. Before launching them. With more than 30 patents and trademarks, both French and international, X.NOV continues to develop and improve its products. Our R&D teams, in collaboration with University Orthopaedic Professors, internationally renowned and talented Surgeons, are developing solutions to improve the medical devices performance for patients, to ensure surgeons and healthcare teams, decreasing operative times, gesture safety in order to contribute to the success of hip and knee replacements.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Funding stage: Private Equity
- Last round: Private Equity (Jan 2017)
- Website: xnov.com
Industries & Categories
Health Care, Manufacturing, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/x-nov-2503408 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.